Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated:  7/19/2011
Daytop Village, Queens Outreach Center
mi
from
Jamaica, NY
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated: 7/19/2011
Daytop Village, Queens Outreach Center
mi
from
Jamaica, NY
Click here to add this to my saved trials
Effect of Cranberry Extract on Infections in Burn Patients
A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Cranberry Extract on the Incidence of Infections in Burn Patients
Status: Enrolling
Updated:  7/19/2011
Saint Elizabeth Regional Medical Center
mi
from
Lincoln, NE
Effect of Cranberry Extract on Infections in Burn Patients
A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Cranberry Extract on the Incidence of Infections in Burn Patients
Status: Enrolling
Updated: 7/19/2011
Saint Elizabeth Regional Medical Center
mi
from
Lincoln, NE
Click here to add this to my saved trials
Virus Surveillance in Pediatric Solid Organ Transplant Recipients
Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant
Status: Enrolling
Updated:  7/20/2011
Seattle Children's Hospital
mi
from
Seattle, WA
Virus Surveillance in Pediatric Solid Organ Transplant Recipients
Virus Surveillance in Pediatric Solid Organ Transplant Recipients: Identifying Risk Factors for PTLD and Other Complications Post-Transplant
Status: Enrolling
Updated: 7/20/2011
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Status: Enrolling
Updated:  7/28/2011
Usa Meddac Mach
mi
from
Columbus, GA
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees
Status: Enrolling
Updated: 7/28/2011
Usa Meddac Mach
mi
from
Columbus, GA
Click here to add this to my saved trials
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
Status: Enrolling
Updated:  8/2/2011
St. John Hospital and Medical Center
mi
from
Grosse Pointe, MI
Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)
Status: Enrolling
Updated: 8/2/2011
St. John Hospital and Medical Center
mi
from
Grosse Pointe, MI
Click here to add this to my saved trials
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated:  8/9/2011
Vanderbilt Emergency Medicine
mi
from
Nashville, TN
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated: 8/9/2011
Vanderbilt Emergency Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated:  8/9/2011
Vanderbilt University Medical Center - Emergency Medicine
mi
from
Nashville, TN
Multicenter Blood Culture Quality Improvement
Multicenter Implementation of a Quality Improvement Program to Reduce Blood Culture Contamination in the Emergency Department
Status: Enrolling
Updated: 8/9/2011
Vanderbilt University Medical Center - Emergency Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).
Prospective Study of Bacteremia and Infection Rates Following Cholangioscopy With the Spyglass Cholangioscope
Status: Enrolling
Updated:  8/11/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).
Prospective Study of Bacteremia and Infection Rates Following Cholangioscopy With the Spyglass Cholangioscope
Status: Enrolling
Updated: 8/11/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters
Understanding HPV Vaccination Among Rural African American Primary Caregivers and Daughters
Status: Enrolling
Updated:  8/12/2011
The Center for Family Research
mi
from
Athens, GA
Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters
Understanding HPV Vaccination Among Rural African American Primary Caregivers and Daughters
Status: Enrolling
Updated: 8/12/2011
The Center for Family Research
mi
from
Athens, GA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Little Rock, AR
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Boulder, CO
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Boulder, CO
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Atlanta, GA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
mi
from
Layton, UT 84041, GA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
mi
from
Layton, UT 84041, GA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Bardstown, KY
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Woburn, MA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Woburn, MA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Bridgeton, MO
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Bridgeton, MO
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
St. Louis, MO
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Rochester, NY
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Syracuse, NY
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Akron, OH
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Cincinnati, OH
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Columbus, OH
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
mi
from
University Heights, OH
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
mi
from
University Heights, OH
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Sellersville, PA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Sellersville, PA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Kingsport, TN
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Layton, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Layton, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Ogden, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Pleasant Grove, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Pleasant Grove, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Provo, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
South Jordan, UT
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
South Jordan, UT
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Norfolk, VA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated:  8/22/2011
Clinical Research Facility
mi
from
Spokane, WA
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
Immunogenicity and Safety of Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Children Aged 4 to 6 Years in the US When Administered Concomitantly With a Fifth Dose Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed.
Status: Enrolling
Updated: 8/22/2011
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
HPV Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
Status: Enrolling
Updated:  9/4/2011
Center for Health and Behavior, Syracuse University
mi
from
Syracuse, NY
Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
HPV Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
Status: Enrolling
Updated: 9/4/2011
Center for Health and Behavior, Syracuse University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Tulane University
mi
from
New Orleans, LA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of Maryland
mi
from
Baltimore, MD
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Children's Hospital - Boston
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Children's Hospital - Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Brigham and Women's Hosp
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Massachusetts General Hospital
mi
from
Boston, MA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Weill Medical College of Cornell University
mi
from
New York, NY
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Duke University
mi
from
Durham, NC
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Case Western Reserve Univ
mi
from
Cleveland, OH
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
The University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
The University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated:  9/6/2011
Univ of Pennsylvania
mi
from
Philadelphia, PA
Initial Treatment of Patients With Immune Thrombocytopenic Purpura
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Status: Enrolling
Updated: 9/6/2011
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials